Abstract:   Objective　To study the prognosis of  hepatoblastoma (HB) in children.　Methods　Retrospective analysis on the clinical data and follow-up of children with HB admitted from September 2010 to February 2015 and sum up the clinical outcome and prognosis. Results   Thirty-six children with HB (23 males and 13 females) were enrolled. The median age on diagnosis was 20 months. All the 36 patients received follow-up, the median follow-up time was 37 months (7～71 months).(1) Of the 36 patients, 8 died. The prognosis of patients with stage Ⅰ or Ⅱ was significantly better than those with stage Ⅲor Ⅳ (P<0.05). The prognosis of patients with fetal type was significantly better than those with other subtypes (P<0.05). (2) Serum AFP level of 35 newly diagnosed cases increased, AFP level of survivors returned to normal after treatment. Of the 8 died patients, 3 patients had AFP elevated when relapsed, 5 cases had a persistently high AFP level after adjuvant chemotherapy. The levels of LDH, CRP, and AST at diagnosis had significant influence on the prognosis (P<0.05). Conclusions　Serum AFP can be a monitoring indicator for recurrence and prognosis of hepatoblastoma.  POG / CCG staging, pathology classification are key points when assessing the prognosis of hepatoblastoma. The prognosis of patients with high levels of LDH, CRP, and AST might be worse.